Carvykti
What Carvykti is used for
Carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least one prior therapy, including an immunomodulatory agent and a proteasome inhibitor have demonstrated disease progression on the last therapy, and are refractory to lenalidomide.
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
- Advanced therapy: a gene, cell or tissue-engineered medicine.
- PRIME: a priority medicine that the EMA supported early because it may meet an unmet need.
Key facts
- Brand
- Carvykti
- Active substance
- ciltacabtagene autoleucel
- Disease area
- Multiple Myeloma
- ATC code
- L01XL05
- Marketing authorisation holder
- Janssen-Cilag International NV
- Authorised in the EU since
- 2022
Official information
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Carvykti used for?
Carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least one prior therapy, including an immunomodulatory agent and a proteasome inhibitor have demonstrated disease progression on the last therapy, and are refractory to lenalidomide.
What is the active substance in Carvykti?
Carvykti contains ciltacabtagene autoleucel.
Who makes Carvykti?
The EU marketing authorisation holder is Janssen-Cilag International NV.
Is Carvykti an orphan medicine?
Yes. Carvykti is designated an orphan medicine in the EU, for a rare disease (Multiple Myeloma).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU